Opendata, web and dolomites

GlucoBeam SIGNED

GlucoBeam: A portable device for pain-free glucose self-monitoring in diabetic patients

Total Cost €


EC-Contrib. €






 GlucoBeam project word cloud

Explore the words cloud of the GlucoBeam project. It provides you a very rough idea of what is the project "GlucoBeam" about.

concentration    day    compliance    disposable    severe    ing    onto    insulin    30s    mellitus    device    proprietary    spectroscopy    patient    diet    aggregated    savings    minimizing    finger    health    digit    complications    commercialization    quality    faced    significantly    collect    billion    requiring    successful    cured    conventional    self    dm    extract    monitoring    glucobeam    strip    approx    prick    relies    sources    costly    acute    exercise    substances    minimum    medium    strategy    foothold    ultimately    empowering    invasive    secure    period    repeating    position    tissue    errors    leverage    optical    market    therapy    droplet    turnover    painful    leads    population    intake    double    people    life    carefully    balancing    levels    blood    patients    uncomfortable    400    innovation    avoiding    signals    treatment    electrochemical    253    critical    million    risk    pain    thereby    society    refined    lancet    diabetes    modern    diabetic    healthcare    scanning    rsp    post    times    smbg    detecting    cornerstone    glucose    added    right    desired    poor    individual    raman    world   

Project "GlucoBeam" data sheet

The following table provides information about the project.


Organization address
city: ODENSE S
postcode: 5260
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Project website
 Total cost 5˙219˙875 €
 EC max contribution 2˙348˙943 € (45%)
 Programme 1. H2020-EU.3.1.4. (Active ageing and self-management of health)
2. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.3.1.6. (Health care provision and integrated care)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-03-01   to  2019-08-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    RSP SYSTEMS A/S DK (ODENSE S) coordinator 2˙348˙943.00


 Project objective

Diabetes mellitus (DM) is one of the largest health challenges currently faced by modern society, affecting over 400 million people in the world. DM cannot be cured, but via well-controlled therapy, a high quality of life with diabetes can be obtained, with a minimum of short- and long-term complications. The key to a successful diabetes therapy is a well-controlled blood glucose level, which is obtained by carefully balancing insulin intake, diet, and exercise and with Self-Monitoring of Blood Glucose (SMBG) as a cornerstone. Conventional SMBG is an invasive test requiring the patient to prick his/her finger with a lancet to extract a blood droplet onto a disposable strip for electrochemical analysis of the glucose concentration. Repeating this uncomfortable and painful task 4-8 times per day leads to severe loss in life quality, often resulting in poor compliance leading to costly complications.

RSP’s proprietary non-invasive SMBG technology relies on the capabilities of Raman spectroscopy for directly detecting individual substances, refined by a unique critical depth optical scanning to collect glucose signals from the right tissue depth range, thus avoiding sources of errors during the measurement. Our GlucoBeam device will enable DM patients to test their glucose levels in around 30s and as often as desired – at no added cost or pain – thereby empowering them to better manage their treatment and minimizing the risk for acute complications.

GlucoBeam’s successful commercialization will position RSP to secure an aggregated turnover of approx. €253 million over the 5 years post-project period. Furthermore, it has the potential to reach double digit billion savings for EU’s healthcare systems and will ultimately lead to significantly improved life quality for the large population of diabetic patients. Moreover, GlucoBeam’s commercialization will allow RSP to set a market foothold in order to leverage its medium term innovation strategy.


List of deliverables.
Project website Websites, patent fillings, videos etc. 2019-05-31 10:46:14

Take a look to the deliverables list in detail:  detailed list of GlucoBeam deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GLUCOBEAM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GLUCOBEAM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.4.;H2020-EU.2.1.1.;H2020-EU.2.3.1.;H2020-EU.3.1.6.)


CLINICOVERY, a versatile, high quality, environmental-friendly, easy to use e-Clinical solution for clinical research

Read More  

SensUS (2018)

SensUS: A non-invasive and quantitative ultrasound (QUS) device for an objective monitoring of the childbirth labour process.

Read More  

ImmuneHunter (2017)

Bioinformatics platform for profiling of health: allowing early and accurate detection of multiple diseases simultaneously

Read More